アルツハイマー病治療薬・診断薬のヨーロッパ市場

Inkwood Researchが発行した調査報告書(INKW807200)
◆英語タイトル:EUROPE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET FORECAST 2018-2026
◆商品コード:INKW807200
◆発行会社(リサーチ会社):Inkwood Research
◆発行日:2018年4月23日
◆ページ数:4
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:ヨーロッパ
◆産業分野:HEALTHCARE, MEDICAL DEVICES
◆販売価格オプション(消費税別)
Single UserUSD1,250 ⇒換算¥133,750見積依頼/購入/質問フォーム
Multi LicenseUSD1,500 ⇒換算¥160,500見積依頼/購入/質問フォーム
Enterprisewide Price (Global Site License)USD2,000 ⇒換算¥214,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はInkwood Research社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Inkwood Research社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

KEY FINDINGSThe Europe Alzheimer’s disease therapeutics and diagnostics market is likely to progress with a 7.62% CAGR over the forecast period of 2018-2026.The region is expected to primarily become a market for generics by 2020 as currently the introduction of generic equivalents of AD therapeutics into the European market has peaked considerably.
MARKET INSIGHTS
The United Kingdom Alzheimer’s disease therapeutics and diagnostics market is mainly driven by the heavy investment made by the government in research for neurodegenerative disease and government’s Alzheimer research conferences to promote the awareness of Alzheimer disease. In France, the market growth is propelled by rising number of studies on Alzheimer’s disease. The German market is expected to dominate this region due to the high prevalence of this diseases in its geriatric population while the Spanish Alzheimer’s disease therapeutics and diagnostics market is primarily being driven by government approvals on strategies for neurodegenerative diseases.
COMPETITIVE INSIGHTS
Merck And Co, Siemens Medical Solutions, Amarantus Bioscience Holdings Inc, Pfizer Inc, Baxter International Inc, Axon Neuroscience Se, F. Hoffmann-La Roche Ag, Ge Healthcare, Abbvie Inc, Diagenic Asa and Cognoptix Inc are few of the established companies in this market.

【レポートの目次】

1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. COMPUTED TOMOGRAPHY IS MAJORLY USED IN THE DIAGNOSTICS OF ALZHEIMER’S DISEASE
3.2.2. THERAPEUTICS MARKET CONSTITUTES THE LARGEST MARKET SHARE
4. MARKET DETERMINANTS
4.1. MARKET DRIVERS
4.1.1. GROWING GERIATRIC POPULATION
4.1.2. RISE IN THE PERVASIVENESS OF ALZHEIMER’S DISEASE
4.1.3. INCREASING HEALTHCARE EXPENDITURE
4.1.4. GOVERNMENT INVESTMENT IN RESEARCH AND DEVELOPMENT
4.2. MARKET RESTRAINTS
4.2.1. STRINGENT GOVERNMENT REGULATIONS
4.2.2. HIGH COST OF THERAPIES USED FOR THE TREATMENT OF ALZHEIMER’S DISEASE
4.3. MARKET OPPORTUNITIES
4.3.1. ADVANCEMENTS IN IN-VITRO DIAGNOSTIC TECHNIQUES
4.3.2. INCREASING R&D INVESTMENT IN THE PERSONALIZED MEDICINES
4.4. MARKET CHALLENGES
4.4.1. LACK OF SKILLED MEDICINAL PRACTITIONERS FOT THE TREATMENT OF ALZHEIMER’S DISEASE
4.4.2. DEARTH OF AWARENESS CONCERNING NEW THERAPIES IN THE ALZHEIMER’S DISEASE
5. MARKET SEGMENTATION
5.1. MARKET BY THERAPEUTICS AND DIAGNOSTIC 2018-2026
5.1.1. THERAPEUTICS
5.1.1.1. THERAPEUTICS BY DRUGS
5.1.1.1.1. MARKETED DRUGS
5.1.1.1.2. PIPELINE DRUGS
5.1.1.2. THERAPEUTICS BY DISEASE STAGE
5.1.1.2.1. LATE STAGE: SEVERE AD
5.1.1.2.2. EARLY/MIDDLE STAGE: MILD TO MODERATE AD
5.1.1.2.3. PRODROMAL STAGE
5.1.1.3. THERAPEUTICS BY GENERIC AND BRANDED
5.1.1.3.1. BRANDED
5.1.1.3.2. GENERIC
5.1.2. DIAGNOSTICS
5.1.2.1. LUMBAR PUNCTURE TEST
5.1.2.2. POSITRON EMISSION TOMOGRAPHY
5.1.2.3. ELECTROENCEPHALOGRAPHY
5.1.2.4. MAGNETIC RESONANCE IMAGING
5.1.2.5. COMPUTED TOMOGRAPHY
5.1.2.6. OTHER DIAGNOSTICS
6. KEY ANALYTICS
6.1. PORTER’S FIVE FORCE MODEL
6.1.1. THREAT OF NEW ENTRANTS
6.1.2. THREATS OF SUBSTITUTE PRODUCT
6.1.3. BARGAINING POWER OF BUYER
6.1.4. BARGAINING POWER OF SUPPLIER
6.1.5. INTENSITY OF COMPETITIVE RIVALRY
6.2. KEY BUYING CRITERIA
6.2.1. PRICE
6.2.2. EFFICIENCY
6.2.3. SAFETY
6.3. ETYMOLOGY OF ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET
6.4. PARENT MARKET ANALYSIS
6.5. INVESTMENTS ANALYSIS
6.5.1. RESEARCH AND DEVELOPMENT
6.5.2. RAW MATERIALS
6.5.3. MANUFACTURING
6.5.4. WHOLESALERS
6.5.5. END USER
6.6. REGULATORY FRAMEWORK
6.7. EUROPE REGULATORY AGENCY
6.8. ALZHEIMER’S DISEASE ETIOLOGY
6.9. PHASES AND STERNNESS OF ALZHEIMER’S DISEASE
6.10. PIPELINE ANALYSIS
6.11. COMPANION DIAGNOSTICS
7. GEOGRAPHICAL ANALYSIS
7.1. EUROPE
7.1.1. THE UNITED KINGDOM
7.1.2. FRANCE
7.1.3. GERMANY
7.1.4. SPAIN
7.1.5. REST OF EUROPE
8. COMPANY PROFILES
8.1. COMPETITIVE LANDSCAPE
8.1.1. MARKET SHARE ANALYSIS
8.2. ABBVIE INC.
8.2.1. COMPANY OVERVIEW
8.2.2. PRODUCT PORTFOLIO
8.2.3. SCOT ANALYSIS
8.2.4. STRATEGIC INITIATIVES
8.3. AMARANTUS BIOSCIENCE HOLDINGS, INC.
8.3.1. COMPANY OVERVIEW
8.3.2. PRODUCT PORTFOLIO
8.3.3. SCOT ANALYSIS
8.3.4. STRATEGIC INITIATIVES
8.4. AXON NEUROSCIENCE SE
8.4.1. COMPANY OVERVIEW
8.4.2. PRODUCT PORTFOLIO
8.4.3. SCOT ANALYSIS
8.4.4. STRATEGIC INITIATIVE
8.5. BAXTER INTERNATIONAL INC.
8.5.1. COMPANY OVERVIEW
8.5.2. PRODUCT PORTFOLIO
8.5.3. SCOT ANALYSIS
8.6. BIOGEN INC.
8.6.1. COMPANY OVERVIEW
8.6.2. PRODUCT PORTFOLIO
8.6.3. SCOT ANALYSIS
8.6.4. STRATEGIC INITIATIVES
8.7. COGNOPTIX INC.
8.7.1. COMPANY OVERVIEW
8.7.2. PRODUCT PORTFOLIO
8.7.3. SCOT ANALYSIS
8.7.4. STRATEGIC INITIATIVES
8.8. DIAGENIC ASA
8.8.1. COMPANY OVERVIEW
8.8.2. PRODUCT PORTFOLIO
8.8.3. SCOT ANALYSIS
8.9. F. HOFFMANN-LA ROCHE AG
8.9.1. COMPANY OVERVIEW
8.9.2. PRODUCT PORTFOLIO
8.9.3. SCOT ANALYSIS
8.9.4. STRATEGIC INITIATIVES
8.10. GE HEALTHCARE
8.10.1. COMPANY OVERVIEW
8.10.2. PRODUCT PORTFOLIO
8.10.3. SCOT ANALYSIS
8.10.4. STRATEGIC INITIATIVES
8.11. MERCK AND CO.
8.11.1. COMPANY OVERVIEW
8.11.2. PRODUCT PORTFOLIO
8.11.3. SCOT ANALYSIS
8.11.4. STRATEGIC INITIATIVES
8.12. PFIZER INC.
8.12.1. COMPANY OVERVIEW
8.12.2. PRODUCT PORTFOLIO
8.12.3. SCOT ANALYSIS
8.12.4. STRATEGIC ANALYSIS
8.13. PIRAMAL ENTERPRISES LTD.
8.13.1. COMPANY OVERVIEW
8.13.2. PRODUCT PORTFOLIO
8.13.3. SCOT ANALYSIS
8.13.4. STRATEGIC INITIATIVES
8.14. SIEMENS MEDICAL SOLUTIONS
8.14.1. COMPANY OVERVIEW
8.14.2. PRODUCT PORTFOLIO
8.14.3. SCOT ANALYSIS
8.14.4. STRATEGIC INITIATIVES
8.15. SUN PHARMA
8.15.1. COMPANY OVERVIEW
8.15.2. PRODUCT PORTFOLIO
8.15.3. SCOT ANALYSIS
8.15.4. STRATEGIC INITIATIVES
TABLE LIST
TABLE 1 EUROPE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2018-2026 ($ MILLION)
TABLE 2 PHARMACOLOGICAL TREATMENT OF BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA (BPSD) OF ALZHEIMER’S
TABLE 3 DIFFERENT BIOMARKERS RELATED TO THE ALZHEIMER’S DISEASE
TABLE 4 EUROPE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2018-2026 ($ MILLION)
TABLE 5 EUROPE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS BY DRUGS 2018-2026 ($ MILLION)
TABLE 6 EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN MARKETED DRUGS 2018-2026 ($ MILLION)
TABLE 7 EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN PIPELINE DRUGS 2018-2026 ($ MILLION)
TABLE 8 EUROPE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN DISEASE STAGE BY DRUGS 2018-2026 ($ MILLION)
TABLE 9 EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN LATE STAGE: SEVERE AD 2018-2026 ($ MILLION)
TABLE 10 EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN EARLY/MIDDLE STAGE: MILD TO MODERATE AD 2018-2026 ($ MILLION)
TABLE 11 EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN PRODROMAL STAGE 2018-2026 ($ MILLION)
TABLE 12 EUROPE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS BY GENERIC AND BRANDED 2018-2026 ($ MILLION)
TABLE 13 EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN BRANDED 2018-2026 ($ MILLION)
TABLE 14 EUROPE ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN GENERIC 2018-2026 ($ MILLION)
TABLE 15 EUROPE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET BY TYPES 2018-2026 ($ MILLION)
TABLE 16 EUROPE ALZHEIMER’S DISEASE DIAGNOSTICS MARKET IN LUMBAR PUNCTURE TEST 2018-2026 ($ MILLION)
TABLE 17 EUROPE ALZHEIMER’S DISEASE DIAGNOSTICS MARKET IN POSITRON EMISSION TOMOGRAPHY 2018-2026 ($ MILLION)
TABLE 18 EUROPE ALZHEIMER’S DISEASE DIAGNOSTICS MARKET IN ELECTROENCEPHALOGRAPHY 2018-2026 ($ MILLION)
TABLE 19 EUROPE ALZHEIMER’S DISEASE DIAGNOSTICS MARKET IN MAGNETIC RESONANCE IMAGING 2018-2026 ($ MILLION)
TABLE 20 EUROPE ALZHEIMER’S DISEASE DIAGNOSTICS MARKET IN COMPUTED TOMOGRAPHY 2018-2026 ($ MILLION)
TABLE 21 EUROPE ALZHEIMER’S DISEASE DIAGNOSTICS MARKET IN OTHER DIAGNOSTICS 2018-2026 ($ MILLION)
TABLE 22 EUROPE ALZHEIMERS DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2018-2026

FIGURES LIST
FIGURE 1 EUROPE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2018-2026 ($ MILLION)
FIGURE 2 COSTS OF CARE FOR PEOPLE WITH ALZHEIMER’S AND OTHER DEMENTIAS 2017 ($ BILLION)
FIGURE 3 EUROPE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS 2018-2026 ($ MILLION)
FIGURE 4 EUROPE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN DIAGNOSTICS2018-2026 ($ MILLION)
FIGURE 5 INVESTMENTS IN ALZHEIMER’S DISEASE TREATMENT
FIGURE 6 ALZHEIMER’S DRUGS IN THE PIPELINE BY TREATMENT FOCUS (NUMBER OF DRUGS)
FIGURE 7 EUROPE ALZHEIMERS DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2018-2026
FIGURE 8 THE UNITED KINGDOM ALZHEIMERS DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2018-2026
FIGURE 9 FRANCE ALZHEIMERS DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2018-2026
FIGURE 10 GERMANY ALZHEIMERS DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2018-2026
FIGURE 11 SPAIN ALZHEIMERS DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2018-2026
FIGURE 12 REST OF EUROPE ALZHEIMERS DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2018-2026
FIGURE 13 MARKET SHARE ANALYSIS OF ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2017 (%)



【レポートのキーワード】

アルツハイマー病治療薬・診断薬

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ アルツハイマー病治療薬・診断薬のヨーロッパ市場(EUROPE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET FORECAST 2018-2026 )]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆